Lyell Immunopharma (LYEL) Total Non-Current Liabilities (2020 - 2025)
Historic Total Non-Current Liabilities for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $76.2 million.
- Lyell Immunopharma's Total Non-Current Liabilities fell 1034.69% to $76.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.2 million, marking a year-over-year decrease of 1034.69%. This contributed to the annual value of $104.8 million for FY2024, which is 1462.48% up from last year.
- Lyell Immunopharma's Total Non-Current Liabilities amounted to $76.2 million in Q3 2025, which was down 1034.69% from $83.5 million recorded in Q2 2025.
- Lyell Immunopharma's Total Non-Current Liabilities' 5-year high stood at $207.0 million during Q2 2021, with a 5-year trough of $76.2 million in Q3 2025.
- Its 5-year average for Total Non-Current Liabilities is $121.1 million, with a median of $94.1 million in 2023.
- In the last 5 years, Lyell Immunopharma's Total Non-Current Liabilities plummeted by 5030.98% in 2023 and then skyrocketed by 1462.48% in 2024.
- Over the past 5 years, Lyell Immunopharma's Total Non-Current Liabilities (Quarter) stood at $193.1 million in 2021, then tumbled by 48.1% to $100.2 million in 2022, then dropped by 8.77% to $91.4 million in 2023, then grew by 14.62% to $104.8 million in 2024, then decreased by 27.31% to $76.2 million in 2025.
- Its last three reported values are $76.2 million in Q3 2025, $83.5 million for Q2 2025, and $90.1 million during Q1 2025.